GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

BGLC · Dec 31, 2024

BioNexus Gene Lab Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001477932-25-002725General Corporate
Capex intensity88thOwn-history percentile · N=16
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

2.39% · OPTIONAL · VALID

Operating cash generation40thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-23.49% · OPTIONAL · VALID

Share-count growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.shares_outstanding

1.70% · CORE · NOT_ENOUGH_HISTORY

Revenue growth53thOwn-history percentile · N=17
Evidence method

Yoy · gp.fundamentals.revenue

-2.66% · CORE · VALID

Inventory pressure25thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

14.60% · OPTIONAL · VALID

Gross margin35thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

13.56% · CORE · VALID

Operating margin35thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-16.55% · CORE · VALID

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

0.50% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History29 statesSelf-history eligible
Sep 30, 20214/6 normalizedLevel 3Dec 31, 20214/6 normalizedLevel 3Mar 31, 20225/6 normalizedLevel 3Jun 30, 20225/6 normalizedLevel 3Sep 30, 20226/6 normalizedLevel 3Dec 31, 20226/6 normalizedLevel 3Mar 31, 20236/6 normalizedLevel 3Jun 30, 20236/6 normalizedLevel 3Sep 30, 20236/6 normalizedAmended as filedDec 31, 20236/6 normalizedLevel 3Mar 31, 20245/5 normalizedLevel 3Jun 30, 20245/5 normalizedLevel 3Sep 30, 20245/5 normalizedLevel 3Dec 31, 20246/8 normalizedLevel 3Mar 31, 20256/7 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20256/9 normalizedLevel 3Mar 31, 20266/7 normalizedLevel 3Jun 30, 20266/7 normalizedLevel 4
Period transition

What moved in the state?

Cash Generation Increased
Previous
-55.49%
Current
-23.49%
Delta
31.99%
Growth Decreased
Previous
3.00%
Current
-2.66%
Delta
-5.67%
Inventory Pressure Decreased
Previous
52.81%
Current
14.60%
Delta
-38.21%
Margin Increased
Previous
12.41%
Current
13.56%
Delta
1.14%
Profitability Increased
Previous
-50.85%
Current
-16.55%
Delta
34.31%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · BGLC Fundamental State →Transitioned To · BGLC CASH_GENERATION_INCREASED →Transitioned To · BGLC GROWTH_DECREASED →Transitioned To · BGLC INVENTORY_PRESSURE_DECREASED →Transitioned To · BGLC MARGIN_INCREASED →Transitioned To · BGLC PROFITABILITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.